An Open-Label, Randomized, Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) study
- Markman, Ben (Primary Chief Investigator (PCI))
- Briggs, Peter (Primary Chief Investigator (PCI))
Project: Research